Navigation Links
Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe
Date:12/3/2009

DALLAS, Dec. 3 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy. MuGard is commercially launched by Access' partner, SpePharm, in six European countries, including the UK, Germany, Italy, Norway, Greece and Sweden. Access is conducting pre-marketing activities, including ramping of commercial production, with the goal of a commercial launch in 1H 2010 in the US. MuGard was granted the CE mark certification in Europe in late 2008 with the labeling "prevention and management of the lesions and symptoms of oral mucositis." Key findings and feedback from SpePharm's ongoing commercial launch and patient assessment project include:

  • Over 15,000 bottles of MuGard have been used by over 2,000 patients since launch.
  • The European patient population includes adult patients undergoing radiotherapy and/or chemotherapy regimens.
  • Patients experience includes those being prescribed and using MuGard prophylactically, as well as those using MuGard following the onset of oral mucositis.
  • Initial feedback continues to reflect that MuGard is well accepted by both patients and healthcare professionals both as a preventative and curative treatment for oral mucositis.
  • Patients and healthcare professionals like MuGard's ready-to-use formulation, and believe it supports treatment compliance by patients.
  • SpePharm is currently gathering feedback from clinicians in the UK, Germany and Italy that are participating in a patient assessment project. SpePharm expects that out of a total of approximately 1,500 patients who will be given MuGard in this project, a consistent number of patient forms will be collected by year end, and the information will be quality checked for potential presentation at a scientific or medical conference or meeting in the first half of 2010.
  • Introduction of MuGard into several additional countries in Europe is anticipated over the next 12 to 18 months.

"As of today, more than 2,000 cancer patients undergoing radiotherapy and/or chemotherapy have been treated with MuGard," stated Jean-Francois Labbe, SpePharm's President & CEO. "We are very pleased with progress to date, and MuGard is well accepted by patients and by healthcare professionals, both as a preventative and curative treatment. MuGard's ready-to-use formulation helps to support treatment compliance by the patients, and we believe is leading to its adoption as treatment-of-choice to prevent and treat oral mucositis."

"Access is pleased with the early acceptance of MuGard as a preventative and curative treatment for oral mucositis," stated Jeffrey Davis, Access' President & CEO. "We hope to be able to leverage SpePharm's early experiences around its launch in Europe to jump start our efforts here throughout the remainder of the year and into 2010."

MuGard is a novel, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 80% of all patients receiving radiotherapy and approximately 40% of all chemotherapy patients develop oral mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop oral mucositis. The market for the prevention and treatment of oral mucositis, expanding to include all patients undergoing chemotherapy and radiotherapy, is estimated to be in excess of $5 billion worldwide. MuGard forms a protective coating over the oral mucosa when swirled gently around the mouth. In a comparison of cancer patients receiving standard mucositis care with those patients receiving MuGard, the incidence and severity of mucositis was significantly lower in the MuGard treated group using a validated scale for the assessment of oral mucositis.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size of the overall market for mucositis products), its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.


Contact: Company                Contact: Investor Relations
Stephen B. Thompson             Donald C. Weinberger/Diana Bittner (media)
Vice President,                 Wolfe Axelrod Weinberger Assoc. LLC
 Chief Financial Officer        (212) 370-4500
Access Pharmaceuticals, Inc.
(214) 905-5100

SOURCE Access Pharmaceuticals, Inc.


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Investor Relations Firm Access IR/PR and The Communications Strategy Group Announce Strategic Alliance
2. avVaa World Health Care Products Inc. Announces Access via Social Media Websites
3. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
4. Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference
5. NuAire Laboratory Economic Stimulus Package -- Free Accessories or Factory Options
6. One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions
7. Understanding Managed Markets: Effective Market Research Structures & Activities to Maximize Payer Access & Insights
8. Access Pharmaceuticals CEO Interviewed on Financial Website
9. Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)
10. FDA Clears Boston Scientifics SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System
11. Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 25, 2017 , ... Proscia Inc. , a software solutions provider ... panelist at 2017 MedCity CONVERGE. His talk, “The Davids vs. the Cancer Goliath,” will ... emerging technology (AI, VR, Big Data) sectors are taking aim at cancer diagnosis and ...
(Date:7/26/2017)... Yorba Linda, Ca (PRWEB) , ... July 25, ... ... will host August 22, attendees will garner a better understanding of the considerations ... for HDR-mediated CRISPR-Cas9 applications. , The use of CRISPR-Cas9 to create targeted double-strand ...
(Date:7/26/2017)... ... July 26, 2017 , ... Spectral imaging is a ... day. This unique capability combines high resolution imaging with spectral analysis. ... unprecedented datasets for chemical analysis, quality control, and decision-making. , Snapshot spectral imaging ...
(Date:7/26/2017)... ... July 26, 2017 , ... Joni Rutter, Director ... Institutes of Health (NIH), will be one of the esteemed presenters at the ... for a multi-stakeholder discussion on the latest advancements in the precision and personalized ...
Breaking Biology Technology:
(Date:6/14/2017)... 15, 2017  IBM (NYSE: IBM ) is introducing several ... dedicated to developing collaboration between startups and global businesses, taking ... During the event, nine startups will showcase the solutions they ... industries. France is ... with a 30 percent increase in the number of startups ...
(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...
(Date:4/17/2017)... MELBOURNE, Florida , April 17, 2017 ... security technology company, announces the filing of its 2016 Annual Report ... Securities and Exchange Commission. ... Report on Form 10-K is available in the Investor Relations section ... well as on the SEC,s website at http://www.sec.gov . ...
Breaking Biology News(10 mins):